After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013, calling it the biggest ...

This tech giant could have even more upside than analysts project.

If you asked Wall Street analysts which quantum computing stock they like the most right now, it would probably be Microsoft ...

The top 10 stock picks include a lot of unfamiliar names, which is to be expected from an Asia-based brokerage. The list ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was up +2.58% at $55.16. This change outpaced the S&P 500's 0.64% gain on the day. Elsewhere, the Dow saw an upswing of 1.23%, while the tech ...

Projected to reach a market size of more than $2 trillion by 2032, the rally in chip stocks is far from over, as AI and the ...

The global cell and gene therapy third-party logistics market size was valued at USD 1.81 billion in 2025 and is predicted to hit around USD 16.95 billion by 2035, rising at a 25.05% CAGR, a study ...

DEM BioPharma, Inc. (DEM Bio), a biopharmaceutical company dedicated to discovering novel targets for solid tumors and developing innovative, first-in-class, cancer medicines, today announced that ...

Is rebalancing your investment portfolio in 2026 a must-do for all investors? “Rebalancing isn’t equally important in every market environment,” says Morningstar portfolio strategist Amy Arnott. “It’s ...